2025 Highlights

Laying the Foundations for the Next Phase of Growth

In 2025, Avalon Pharma accelerated its transformation into a more diversified healthcare platform, with a stronger focus on specialized treatments and a deeper presence at the institutional level. The year was not merely a year of performance, but rather a year for renewing strategic momentum and preparing for a new phase leading up to 2030.

Strategic Partnerships: Building an Advanced Future Oriented Portfolio

During the year, a number of high-impact strategic partnerships were implemented, strengthening our capabilities in specialized and advanced treatment areas. These partnerships contributed to expanding the depth of our therapeutic portfolio, enhancing our regional presence, and establishing Avalon Pharma as a trusted partner for global companies seeking sustainable access to regional markets.

These steps also reflect a deliberate transformation from a strong local manufacturing company into a regional platform capable of competing in high-value therapeutic sectors, aligned with national healthcare priorities.

Market Leadership, Global Recognition, and Institutional Credibility

Avalon Pharma continued to strengthen its position among leading national companies, while continuing to achieve advanced ratings and classifications in its therapeutic sectors. Our key brands maintained leadership positions, reflecting a highly disciplined, scientifically informed, and market-savvy approach.

The High Recognition of one of our leading brands confirms Avalon Pharma’s ability to develop products capable of competing beyond local markets. This achievement demonstrates the scalability of our business model and supports our ambition for regional and international expansion by 2030.

Beyond classifications, 2025 saw a growth in institutional confidence in Avalon Pharma from regulatory authorities, partners, healthcare providers, and investors, which enhances trust in our long-term strategic plans.

Investment in Human Capital: Launch of Avalon Pharma Training Academy

Believing that sustainable development begins with the human element, we launched the Avalon Pharma Training Academy as an organized and future-oriented platform to develop leadership, enhance technical competencies, and establish a culture of continuous learning at all levels. This initiative embodies our commitment to developing national talents and building a leadership pipeline capable of guiding Avalon Pharma’s ambitions in the coming decade.

Corporate culture and excellence as a workplace

It reflects Avalon’s attainment of a “distinguished work environment”, where we continuously commit to building a culture based on performance and values simultaneously. With our expansion, we continue to strengthen a work environment that emphasizes accountability, flexibility, opportunities, and shared ambition.

The corporate culture is not just a supportive element, but a strategic competitive advantage.

Responsible growth and national contribution

The recognition of Avalon Pharma in the field of social responsibility by the Ministry of Human Resources reflects our alignment with the objectives of the Kingdom’s Vision 2030, our commitment to contributing to economic development, enhancing local content, and supporting the community.

Future Outlook

With the approach of 2030, Avalon Pharma’s focus remains clear:

• Deepening our presence in specialized and advanced treatments.
• Enhancing manufacturing and localization capabilities, and expanding our regional footprint.
• Strengthening corporate governance, developing competencies, and enhancing operational excellence.

The year 2025 was a year for laying the foundations and building capabilities, while the next phase will be characterized by a controlled and well-planned expansion toward establishing a significant regional pharmaceutical platform, capable of delivering sustainable value to patients, partners, employees, and shareholders alike.